NO20061866L - Vevsbeskyttende cytokiner for behandling og forebyggelse av sepsis og dannelse av adhesjoner - Google Patents
Vevsbeskyttende cytokiner for behandling og forebyggelse av sepsis og dannelse av adhesjonerInfo
- Publication number
- NO20061866L NO20061866L NO20061866A NO20061866A NO20061866L NO 20061866 L NO20061866 L NO 20061866L NO 20061866 A NO20061866 A NO 20061866A NO 20061866 A NO20061866 A NO 20061866A NO 20061866 L NO20061866 L NO 20061866L
- Authority
- NO
- Norway
- Prior art keywords
- sepsis
- formation
- adhesions
- prevention
- treatment
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 2
- 108090000695 Cytokines Proteins 0.000 title abstract 2
- 206010040047 Sepsis Diseases 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 230000002669 organ and tissue protective effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 206010053159 Organ failure Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En fremgangsmåte for å behandle, forebygge, forsinke igangsettelsen av og/eller redusere virkningene av proinflammatoriske cytokiner i tilstander som inkluderer, men ikke er begrenset til, sepsis, adhesjonsdannelse, sår, organsvikt, kronisk sykdom, generelle inflammatoriske tilstander som er resultatet av infeksjon, arrdannelse som er resultatet av skade og innsnitt, og kombinasjoner derav.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50614903P | 2003-09-29 | 2003-09-29 | |
PCT/US2004/031789 WO2005032467A2 (en) | 2003-09-29 | 2004-09-29 | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061866L true NO20061866L (no) | 2006-06-27 |
Family
ID=34421527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061866A NO20061866L (no) | 2003-09-29 | 2006-04-27 | Vevsbeskyttende cytokiner for behandling og forebyggelse av sepsis og dannelse av adhesjoner |
Country Status (15)
Country | Link |
---|---|
US (1) | US7645733B2 (no) |
EP (1) | EP1670492A4 (no) |
JP (1) | JP2007517769A (no) |
KR (1) | KR20070008519A (no) |
CN (1) | CN1897959A (no) |
AU (1) | AU2004277954A1 (no) |
BR (1) | BRPI0414887A (no) |
CA (1) | CA2539440A1 (no) |
EA (1) | EA010650B1 (no) |
IL (1) | IL174577A0 (no) |
IS (1) | IS8359A (no) |
MX (1) | MXPA06003234A (no) |
NO (1) | NO20061866L (no) |
WO (1) | WO2005032467A2 (no) |
ZA (1) | ZA200603396B (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US7767643B2 (en) * | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
NZ565937A (en) | 2005-08-05 | 2011-09-30 | Araim Pharmaceuticals Inc | Tissue protective peptides and uses thereof |
EP2120998B1 (en) | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
KR100876979B1 (ko) * | 2007-06-12 | 2009-01-07 | 성균관대학교산학협력단 | 알로에 추출물을 유효성분으로 하는 패혈증 및 패혈증성쇼크 치료용 약학 조성물 |
US20100298219A1 (en) * | 2008-01-22 | 2010-11-25 | Anthony Cerami | Method of treating cancer, neoplastic disorders, and symptoms thereof with compounds |
ES2539124T3 (es) | 2008-01-22 | 2015-06-26 | Araim Pharmaceuticals, Inc. | Péptidos y análogos peptídicos protectores de tejido para la prevención y el tratamiento de enfermedades y trastornos asociados con daño tisular |
EP2350646B1 (en) * | 2008-10-28 | 2016-01-13 | Assistance Publique - Hôpitaux de Paris | Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock |
RU2523263C2 (ru) * | 2011-10-20 | 2014-07-20 | Максуд Абдуразакович Халилов | Способ профилактики спаечной болезни |
WO2013151910A1 (en) * | 2012-04-02 | 2013-10-10 | Saint Louis University | Methods and compositions for reducing the incidence of post-surgical adhesions |
RU2529408C1 (ru) * | 2013-09-17 | 2014-09-27 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения Российской Федерации | Способ лечения спаечной болезни |
US10260111B1 (en) | 2014-01-20 | 2019-04-16 | Brett Eric Etchebarne | Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample |
JP2019523633A (ja) | 2016-04-29 | 2019-08-29 | アライム ファーマシューティカルズ,インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4343782A (en) | 1978-04-20 | 1982-08-10 | Shapiro Howard M | Cytological assay procedure |
US4658019A (en) | 1979-04-26 | 1987-04-14 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells |
JPS6045849B2 (ja) | 1980-08-25 | 1985-10-12 | 林原 健 | ヒトエリトロポエチンの製造方法 |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
JPS6197229A (ja) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
US4835260A (en) | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
DE3729863A1 (de) | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
DE3923963A1 (de) | 1989-07-20 | 1991-01-31 | Behringwerke Ag | Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
WO1991005867A1 (en) | 1989-10-13 | 1991-05-02 | Amgen Inc. | Erythropoietin isoforms |
CA2045175C (en) | 1989-11-06 | 2003-03-18 | Arthur I. Skoultchi | Production of proteins using homologous recombination |
DE779362T1 (de) | 1989-12-22 | 2001-04-05 | Applied Research Systems | DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen |
US5292654A (en) | 1990-12-13 | 1994-03-08 | Whitehead Institute For Biomedical Research | Mutant EPO receptor and uses therefor |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
JP3156236B2 (ja) | 1991-09-30 | 2001-04-16 | 雪印乳業株式会社 | 記憶障害改善治療剤 |
JP3537151B2 (ja) | 1991-12-26 | 2004-06-14 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
US5625035A (en) | 1992-06-05 | 1997-04-29 | The Regents, University Of California | Erythropoietin binding protein from mammalian serum |
US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
US5661125A (en) | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
HUT73876A (en) | 1993-04-29 | 1996-10-28 | Abbott Lab | Erythropoietin analog compositions and methods |
US5700909A (en) | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
JPH09501833A (ja) | 1993-08-16 | 1997-02-25 | リー,ジョン・ワイ | ヒトエリスロポイエチン受容体断片及びそれに対する抗体 |
IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
US5859001A (en) | 1996-01-11 | 1999-01-12 | University Of Florida Research Foundation, Inc. | Neuroprotective effects of polycyclic phenolic compounds |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
US5604198A (en) | 1994-05-12 | 1997-02-18 | Poduslo; Joseph F. | Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents |
US5763198A (en) | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
US5835382A (en) | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
US20020052309A1 (en) | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
IL130964A0 (en) | 1997-01-16 | 2001-01-28 | Cytel Corp | Practical in vitro sialylation of recombinant glycoproteins |
EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
US6548296B1 (en) | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
US6274158B1 (en) | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
ATE271376T1 (de) | 1998-02-23 | 2004-08-15 | Cilag Ag Int | Liposomale erythropoietin-dispersion |
US6291661B1 (en) | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
US20030118547A1 (en) | 2000-01-27 | 2003-06-26 | Vandenberg Grant William | Composition for intestinal delivery |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
US20020061849A1 (en) | 2000-05-02 | 2002-05-23 | Soren Nielsen | Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
JP2004528001A (ja) | 2000-05-12 | 2004-09-16 | ネオーズ テクノロジーズ, インコーポレイテッド | インビトロにおけるフコシル化組換えグリコペプチド |
US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
KR100401296B1 (ko) | 2000-12-27 | 2003-10-11 | 드림바이오젠 주식회사 | 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법 |
US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
US7300916B2 (en) | 2001-02-27 | 2007-11-27 | Yoshiko Yasuda | Preventives/remedies for thickened scar, keloid or chronic arthritic diseases |
US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
KR100467750B1 (ko) | 2001-11-29 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
KR100467751B1 (ko) | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
CA2485365A1 (en) | 2002-05-13 | 2003-11-20 | Modigenetech Ltd. | Ctp-extended erythropoietin |
US7300915B2 (en) | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
NZ537306A (en) | 2002-07-01 | 2008-11-28 | Kenneth S Warren Inst Inc | Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier |
US20050176627A1 (en) | 2002-09-09 | 2005-08-11 | Anthony Cerami | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
CA2519803A1 (en) | 2003-03-27 | 2004-10-14 | Janssen Pharmaceutica N.V. | Use of erythropoietin in stroke recovery |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
US20060216757A1 (en) | 2003-04-25 | 2006-09-28 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
US20080045409A1 (en) | 2006-08-16 | 2008-02-21 | Buarque De Macedo Pedro M | Ceramic catalysts |
-
2004
- 2004-09-29 ZA ZA200603396A patent/ZA200603396B/en unknown
- 2004-09-29 JP JP2006534015A patent/JP2007517769A/ja active Pending
- 2004-09-29 EP EP04785193A patent/EP1670492A4/en not_active Withdrawn
- 2004-09-29 WO PCT/US2004/031789 patent/WO2005032467A2/en active Application Filing
- 2004-09-29 AU AU2004277954A patent/AU2004277954A1/en not_active Abandoned
- 2004-09-29 MX MXPA06003234A patent/MXPA06003234A/es unknown
- 2004-09-29 CA CA002539440A patent/CA2539440A1/en not_active Abandoned
- 2004-09-29 EA EA200600695A patent/EA010650B1/ru not_active IP Right Cessation
- 2004-09-29 CN CNA2004800352522A patent/CN1897959A/zh active Pending
- 2004-09-29 US US10/573,905 patent/US7645733B2/en not_active Expired - Fee Related
- 2004-09-29 KR KR1020067008389A patent/KR20070008519A/ko not_active Application Discontinuation
- 2004-09-29 BR BRPI0414887-8A patent/BRPI0414887A/pt not_active IP Right Cessation
-
2006
- 2006-03-17 IS IS8359A patent/IS8359A/is unknown
- 2006-03-27 IL IL174577A patent/IL174577A0/en unknown
- 2006-04-27 NO NO20061866A patent/NO20061866L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1897959A (zh) | 2007-01-17 |
AU2004277954A1 (en) | 2005-04-14 |
EP1670492A4 (en) | 2009-07-08 |
BRPI0414887A (pt) | 2006-12-12 |
EA010650B1 (ru) | 2008-10-30 |
IS8359A (is) | 2006-03-17 |
ZA200603396B (en) | 2007-11-28 |
EA200600695A1 (ru) | 2006-08-25 |
US7645733B2 (en) | 2010-01-12 |
WO2005032467A3 (en) | 2005-07-21 |
WO2005032467A2 (en) | 2005-04-14 |
EP1670492A2 (en) | 2006-06-21 |
JP2007517769A (ja) | 2007-07-05 |
CA2539440A1 (en) | 2005-04-14 |
KR20070008519A (ko) | 2007-01-17 |
US20070129293A1 (en) | 2007-06-07 |
IL174577A0 (en) | 2006-08-20 |
MXPA06003234A (es) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061866L (no) | Vevsbeskyttende cytokiner for behandling og forebyggelse av sepsis og dannelse av adhesjoner | |
BRPI0514630A (pt) | alfa-mercaptoacetanilidas e s-triazolila como inibidores de transcriptase reversa de hiv | |
NO20044658L (no) | Anvendelse av osteoprotegerin til behandling og/eller forhindring av fibrotiske sykdommer | |
NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
NO20044459L (no) | Anvendelse av IL-18-inhibitorer for behandlingen og/eller forebyggingen av perifere vaskulaere sykdomrner | |
ATE555810T1 (de) | Mittel zur behandlung oder prävention von verdauungsgeschwüren | |
ATE551052T1 (de) | Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz | |
NO20055986L (no) | Forbindelse for behandling og forebygging av virale infeksjonssykdommer | |
NO20065079L (no) | Materialer og metoder for behandling av koaguleringssykdommer | |
WO2007104946A3 (en) | Medicaments and proteins based on tgf-beta monomers for the treatment of wounds | |
SE0200667D0 (sv) | Novel use of cytokine inhibitors | |
WO2020047352A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
NO20051681L (no) | Lysaldring av hud og aktinskadebehandling | |
WO2005060960A3 (en) | Use of histamine to treat bone disease | |
WO2004032709A3 (en) | Inhibition of src for treatment of reperfusion injury related to revascularization | |
NO20073104L (no) | Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser | |
WO2004009773A3 (en) | Methods and compositions for activating or inhibiting vegf-d and vegf-c | |
WO2004009030A3 (en) | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof | |
WO2004098599A3 (en) | Proton pump inhibitors for the treatment of lower abdominal disorders | |
WO2003063927A3 (en) | Compositions and methods to treat gastrointestinal disorders | |
SE0200005L (sv) | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet | |
EP4234022A3 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
WO2008001113A3 (en) | Use of wnt5a for inhibiting scarring | |
WO2003094967A3 (en) | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders | |
WO2003068156A3 (en) | Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |